Comparative Pharmacology
Head-to-head clinical analysis: CORTENEMA versus FLOVENT DISKUS 100.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTENEMA versus FLOVENT DISKUS 100.
CORTENEMA vs FLOVENT DISKUS 100
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to the glucocorticoid receptor, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, decrease cytokine production, and suppress inflammatory cell migration and activation in the colonic mucosa.
Fluticasone propionate is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity. It binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as cytokines, leukotrienes, and prostaglandins. It reduces airway hyperresponsiveness and suppresses eosinophil activity.
One enema (100 mg hydrocortisone in 60 mL) administered rectally once daily, preferably at bedtime, for 21 days or until clinical response.
100 mcg inhaled orally twice daily
None Documented
None Documented
1.8-3.5 hours (plasma); due to rectal administration and low systemic absorption, clinical effects persist longer than plasma levels suggest
The terminal elimination half-life of fluticasone propionate is approximately 7.8 hours (range 5-11 hours) following inhalation. This supports twice-daily dosing, though the therapeutic effect is driven by local lung retention rather than systemic half-life.
Primarily hepatic metabolism with renal excretion of inactive metabolites; <5% unchanged in urine; biliary/fecal elimination of metabolites accounts for ~80%
Fluticasone propionate is primarily eliminated via hepatic metabolism (CYP3A4) with less than 5% of a dose excreted unchanged in urine. Fecal excretion accounts for approximately 90% of the absorbed dose (as metabolites). Biliary elimination is minimal.
Category C
Category C
Corticosteroid
Corticosteroid